AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things get going
Target
Upside 486%
Price (€) 1.95
Market Cap (€M) 71.2
Perf. 1W: -12.9%
Perf. 1M: -42.4%
Perf. 3M: -65.2%
Perf Ytd: -60.8%
10 day relative perf. to stoxx600: -36.8%
20 day relative perf. to stoxx600: -41.1%
EPS change26/09/2022

Minor changes after H1 22

Change in EPS2022 : € -0.32 vs -0.23ns
2023 : € -0.35 vs -0.25ns

We have only changed our short-term estimates after the release of the H1 22 results. These changes are minor and are limited to FY23-24) even if they look more significant in EPS terms due to the fact that the result is a small loss, implying that any change to our numbers translates into an apparent bigger change in percentage terms. The impact on our valuation of the stock is thus marginal.



Updates

03 Apr 24 Earnings/sales releases
Patience is a virtue… hopefully

28 Feb 24 Financing issue
Securing the financing needs

08 Feb 24 Strategic Plan
No news is not always good news...

03 Jan 24 Other news/comments
A new distribution agreement in Northern Europe

27 Mar 23 EPS change
No real news in the FY22 results.

23 Mar 23 Earnings/sales releases
FY22: not much to learn from the release

26 Sep 22 EPS change
Minor changes after H1 22

.